New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
14:36 EDTTEVA, MYLTeva unit prevails over conspiracy claims related to Provigil, Law360 says
A Pennsylvania federal judge ruled that settlements Teva Pharmaceutical's (TEVA) Cephalon unit agreed to with generic-drug makers did not amount to a conspiracy to keep cheaper versions of narcolepsy drug Provigil off the market, as alleged by Apotex, reported Law360 last night. Cephalon, along with Mylan (MYL) and the other defendants, were granted summary judgment, according to the report. Reference Link
News For TEVA;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
08:15 EDTMYLPfizer wins SUTENT patent case In Delaware District Court
Pfizer (PFE) announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. Pfizer filed suit in June 2010 after Mylan (MYL) applied to the U.S. Food and Drug Administration to market a generic version of SUTENT prior to the expiration of the patents covering sunitinib malate and its uses. After a four-day trial, the Court agreed that Mylan infringed the valid patents covering SUTENT.
06:22 EDTMYLMylan, Abbott enter into amendment, still see deal closing in 1Q15
Subscribe for More Information
October 22, 2014
11:59 EDTMYLStocks with call strike movement; MYL AMZN
Subscribe for More Information
09:16 EDTMYLAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
October 20, 2014
08:04 EDTMYLGerman fund pressured to sell Mylan stake over drug used in executions, FT says
Subscribe for More Information
07:20 EDTMYLInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use